Revolution Medicines, Inc.

Contributing Author

Recent Articles by Revolution Medicines, Inc.

Oct-23	Revolution Medicines Presents Overall Survival Data for RASONQUE (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026 RVMD GlobeNewswire
Oct-21	Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026 RVMD GlobeNewswire
Oct-20	Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer RVMD +7.91% GlobeNewswire
Oct-15	Revolution Medicines' RASONQUE (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer RVMD GlobeNewswire
Oct-05	Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer RVMD GlobeNewswire
Sep-14	Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer RVMD GlobeNewswire
Sep-02	New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer RVMD GlobeNewswire
Aug-26	U.S. FDA Approves Revolution Medicines' RASONQUE (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer RVMD GlobeNewswire
Aug-05	Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress RVMD GlobeNewswire
Jul-29	Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026 RVMD RVMD +6.22% GlobeNewswire
Jul-22	Revolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer RVMD GlobeNewswire
Jul-07	European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process RVMD GlobeNewswire
Jul-02	Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 RVMD GlobeNewswire
Jun-24	Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 RVMD GlobeNewswire
Jun-23	Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer RVMD GlobeNewswire
Jun-22	Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. RVMD GlobeNewswire
May-31	Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer RVMD GlobeNewswire
May-21	Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation RVMD GlobeNewswire
May-06	Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer RVMD RVMD -5.67% GlobeNewswire
May-06	Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress RVMD RVMD -5.67% GlobeNewswire
Apr-29	Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026 RVMD GlobeNewswire
Apr-21	Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting RVMD GlobeNewswire
Apr-21	Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting RVMD GlobeNewswire
Apr-21	Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting RVMD GlobeNewswire
Apr-19	Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting RVMD GlobeNewswire
Apr-17	Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares RVMD GlobeNewswire
Apr-15	Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes RVMD GlobeNewswire
Apr-13	Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes RVMD +41.35% RVMD +7.86% GlobeNewswire
Apr-13	Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer RVMD +41.35% GlobeNewswire
Apr-02	Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer RVMD GlobeNewswire
Mar-17	Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting RVMD GlobeNewswire
Feb-25	Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress RVMD GlobeNewswire
Feb-24	Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference RVMD GlobeNewswire
Feb-18	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 RVMD GlobeNewswire
Feb-04	Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 RVMD GlobeNewswire
Jan-29	Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor RVMD GlobeNewswire
Jan-08	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib RVMD GlobeNewswire
Jan-05	Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference RVMD GlobeNewswire
Dec-18	Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy RVMD GlobeNewswire
Nov-05	Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress RVMD GlobeNewswire
Nov-04	Revolution Medicines to Participate in November 2025 Investor Conferences RVMD GlobeNewswire
Oct-29	Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 RVMD GlobeNewswire
Oct-27	Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer RVMD +6.44% GlobeNewswire
Oct-22	Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor RVMD GlobeNewswire
Oct-16	Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program RVMD +8.90% GlobeNewswire
Sep-29	Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer RVMD GlobeNewswire
Sep-10	Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma RVMD RVMD +14.31% GlobeNewswire
Aug-06	Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress RVMD GlobeNewswire
Jul-30	Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 RVMD GlobeNewswire
Jul-24	Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor RVMD GlobeNewswire
Jul-23	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib RVMD GlobeNewswire
Jul-09	Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates RVMD +5.71% GlobeNewswire
Jun-30	Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors RVMD GlobeNewswire
Jun-24	Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers RVMD GlobeNewswire
Jun-23	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations RVMD GlobeNewswire
May-14	Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer RVMD GlobeNewswire
May-07	Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress RVMD RVMD +11.29% GlobeNewswire

Revolution Medicines, Inc.

Recent Articles by Revolution Medicines, Inc.

Upgrade your Finviz experience